Triple diagnosis of Wiedemann-Steiner, Waardenburg and DLG3-related intellectual disability association found by WES: A case report.


Journal

The journal of gene medicine
ISSN: 1521-2254
Titre abrégé: J Gene Med
Pays: England
ID NLM: 9815764

Informations de publication

Date de publication:
08 2020
Historique:
received: 08 10 2019
revised: 19 02 2020
accepted: 21 03 2020
pubmed: 5 4 2020
medline: 7 8 2021
entrez: 5 4 2020
Statut: ppublish

Résumé

The development of whole-exome sequencing (WES) and whole-genome sequencing (WGS) for clinical purposes now allows the identification of multiple pathogenic variants in patients with a rare disease. This occurs even when a single causative gene was initially suspected. We report the case of an 8-year-old patient with global developmental delays and dysmorphic features, with a possibly pathogenic variant in three distinct genes. Trio-based exome sequencing was performed by IntegraGen SA (Evry, France), on an Illumina HiSeq4000 (Illumina, San Diego, CA, USA). Sanger sequencing was performed to confirm the variants that were found. WES showed the presence of three possibly deleterious variants: KMT2A: c.9068delA;p.Gln3023Argfs*3 de novo, PAX3: c.530C>G;p.Ala177Gly de novo and DLG3: c.127delG;p.Asp43Metfs*22 hemizygous inherited from the mother. KMT2A pathogenic variants are involved in Wiedemann-Steiner syndrome, and PAX3 is the gene responsible for Waardenburg syndrome. DLG3 variants have been described in a non-syndromic X-related intellectual disability. Considering the dysmorphic features and intellectual disability presented by this patient, these three variants were imputed as pathogenic and their association was considered responsible for his phenotype. Dual molecular diagnoses have already been found by WES in several cohorts with an average of diagnostic yield of 7%. This case demonstrates and reminds us of the importance of analyzing exomes rigorously and exhaustively because, in some cases (< 10%), it can explain superimposed traits or blended phenotypes.

Sections du résumé

BACKGROUND
The development of whole-exome sequencing (WES) and whole-genome sequencing (WGS) for clinical purposes now allows the identification of multiple pathogenic variants in patients with a rare disease. This occurs even when a single causative gene was initially suspected. We report the case of an 8-year-old patient with global developmental delays and dysmorphic features, with a possibly pathogenic variant in three distinct genes.
METHODS
Trio-based exome sequencing was performed by IntegraGen SA (Evry, France), on an Illumina HiSeq4000 (Illumina, San Diego, CA, USA). Sanger sequencing was performed to confirm the variants that were found.
RESULTS
WES showed the presence of three possibly deleterious variants: KMT2A: c.9068delA;p.Gln3023Argfs*3 de novo, PAX3: c.530C>G;p.Ala177Gly de novo and DLG3: c.127delG;p.Asp43Metfs*22 hemizygous inherited from the mother. KMT2A pathogenic variants are involved in Wiedemann-Steiner syndrome, and PAX3 is the gene responsible for Waardenburg syndrome. DLG3 variants have been described in a non-syndromic X-related intellectual disability.
CONCLUSIONS
Considering the dysmorphic features and intellectual disability presented by this patient, these three variants were imputed as pathogenic and their association was considered responsible for his phenotype. Dual molecular diagnoses have already been found by WES in several cohorts with an average of diagnostic yield of 7%. This case demonstrates and reminds us of the importance of analyzing exomes rigorously and exhaustively because, in some cases (< 10%), it can explain superimposed traits or blended phenotypes.

Identifiants

pubmed: 32246869
doi: 10.1002/jgm.3197
doi:

Substances chimiques

DLG3 protein, human 0
KMT2A protein, human 0
Nuclear Proteins 0
PAX3 Transcription Factor 0
PAX3 protein, human 0
Transcription Factors 0
Myeloid-Lymphoid Leukemia Protein 149025-06-9
Histone-Lysine N-Methyltransferase EC 2.1.1.43

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e3197

Informations de copyright

© 2020 John Wiley & Sons, Ltd.

Références

Jones WD, Dafou D, McEntagart M, et al. De novo mutations in MLL cause Wiedemann-Steiner syndrome. Am J Hum Genet. 2012;91:358-364.
Wiel L, Baakman C, Gilissen D, Veltman JA, Vriend G, Gilissen C. MetaDome: pathogenicity analysis of genetic variants through aggregation of homologous human protein domains. Hum Mutat. 2019;40(8):1030-1038.humu.23798.
Rentzsch P, Witten D, Cooper GM, Shendure J, Kircher M. CADD: predicting the deleteriousness of variants throughout the human genome. Nucleic Acids Res. 2019;47:D886-D894.
Baldwin CT, Hoth CF, Amos JA, da-Silva EO, Milunsky A. An exonic mutation in the HuP2 paired domain gene causes Waardenburg's syndrome. Nature. 1992;355:637-638.
Baldwin CT, Hoth CF, Macina RA, Milunsky A. Mutations in PAX3 that cause Waardenburg syndrome type I: ten new mutations and review of the literature. Am J Med Genet. 1995;58:115-122.
Tamayo ML, Gelvez N, Rodriguez M, et al. Screening program for Waardenburg syndrome in Colombia: clinical definition and phenotypic variability. Am J Med Genet A. 2008;146A:1026-1031.
Pardono E, van Bever Y, van den Ende J, et al. Waardenburg syndrome: clinical differentiation between types I and II. Am J Med Genet A. 2003;117A:223-235.
Tarpey P, Parnau J, Blow M, et al. Mutations in the DLG3 gene cause nonsyndromic X-linked mental retardation. Am J Hum Genet. 2004;75:318-324.
Gieldon L, Mackenroth L, Betcheva-Krajcir E, et al. Skewed X-inactivation in a family with DLG3- associated X-linked intellectual disability. Am J Med Genet a. 2017;173:2545-2550.
Köhler S, Carmody L, Vasilevsky N, et al. Expansion of the human phenotype ontology (HPO) knowledge base and resources. Nucleic Acids Res. 2019;47:D1018-D1027.
Robinson JF, Katsanis N. Oligogenic Disease. In: Speicher MR, Motulsky AG, Antonarakis SE, editors. Vogel and Motulsky's Human Genetics [Internet]. Berlin, Heidelberg: Springer Berlin Heidelberg; 2010 [cité 12 juin 2019]. p. 243-62. Disponible Sur: http://link.springer.com/10.1007/978-3-540-37654-5_8
Shaffer LG, American college of medical genetics professional practice and guidelines committee. American College of Medical Genetics Guideline on the cytogenetic evaluation of the individual with developmental delay or mental retardation. Genet Med off J Am Coll Med Genet. 2005;7:650-654.
Miller DT, Adam MP, Aradhya S, et al. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet. 2010;86:749-764.
Yang Y, Muzny DM, Reid JG, et al. Clinical whole-exome sequencing for the diagnosis of Mendelian disorders. N Engl J Med. 2013;369:1502-1511.
Posey JE, Rosenfeld JA, James RA, et al. Molecular diagnostic experience of whole-exome sequencing in adult patients. Genet Med. 2016;18:678-685.
Rossi M, El-Khechen D, Black MH, Farwell Hagman KD, Tang S, Powis Z. Outcomes of diagnostic exome sequencing in patients with diagnosed or suspected autism Spectrum disorders. Pediatr Neurol. 2017;70:34-43.
Posey JE, Harel T, Liu P, et al. Resolution of disease phenotypes resulting from multilocus genomic variation. N Engl J Med. 2017;376:21-31.
Smith ED, Blanco K, Sajan SA, et al. A retrospective review of multiple findings in diagnostic exome sequencing: half are distinct and half are overlapping diagnoses. Genet Med off J Am Coll Med Genet. 2019;21:2199-2207.

Auteurs

Thibaut Matis (T)

Service de Génétique Médicale, CHU Bordeaux, Bordeaux, France.

Vincent Michaud (V)

Service de Génétique Médicale, CHU Bordeaux, Bordeaux, France.

Julien Van-Gils (J)

Service de Génétique Médicale, CHU Bordeaux, Bordeaux, France.

Virginie Raclet (V)

Service de Génétique Médicale, CHU Bordeaux, Bordeaux, France.

Claudio Plaisant (C)

Service de Génétique Médicale, CHU Bordeaux, Bordeaux, France.

Patricia Fergelot (P)

Service de Génétique Médicale, CHU Bordeaux, Bordeaux, France.

Eulalie Lasseaux (E)

Service de Génétique Médicale, CHU Bordeaux, Bordeaux, France.

Benoit Arveiler (B)

Service de Génétique Médicale, CHU Bordeaux, Bordeaux, France.

Aurélien Trimouille (A)

Service de Génétique Médicale, CHU Bordeaux, Bordeaux, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH